The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy
暂无分享，去创建一个
[1] R. Koole,et al. Perilesional IL-2 treatment of a VX2 head-and-neck cancer model can induce a systemic anti-tumour activity. , 2000, Anticancer research.
[2] H. Heinzer,et al. Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). , 1999, Anticancer research.
[3] J. Battermann,et al. Local low-dose IL-2 therapy. , 1999, Hepato-gastroenterology.
[4] P. D. De Mulder,et al. PEG‐IL‐2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclopphosphamide , 1994, International journal of cancer.
[5] P. D. De Mulder,et al. Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma. , 1993, Anticancer research.
[6] R. Maas,et al. Tumour regression by IL-2 mediated stagnation of blood flow. , 1991, In vivo.
[7] R. Maas,et al. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. , 1989, Cancer research.
[8] J. Vaage. Local and systemic effects during interleukin-2 therapy of mouse mammary tumors. , 1987, Cancer research.
[9] G. Forni,et al. Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. , 1985, Journal of immunology.